de Moel EC, et al. - In 381 seropositive rheumatoid arthritis (RA) cases from the IMPROVED study, the authors estimated longitudinal variations in RA-autoantibody levels, the relationship between these changes and activity score (DAS) as well as consequences of treatment, and also the impact of immunosuppressive treatment intensity on different levels of the disease. They estimated IgG, IgM, and IgA of anti-CCP2 and anti-CarP; IgM and IgA of RF; and IgG against 4 citrullinated and 2 acetylated peptides at 4-month intervals over the first year of therapy. They noted a significant drop of 10% in rheumatoid factor (RF) IgM levels, a representative autoantibody, after restarting prednisone and an increase of 15% aU/mL after reducing methotrexate (MTX). No association between autoantibody levels and DAS over time or EULAR response was recorded.